NASDAQ:CBIO Crescent Biopharma Q1 2026 Earnings Report $16.89 +0.12 (+0.72%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$16.89 0.00 (-0.03%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Crescent Biopharma EPS ResultsActual EPS-$0.70Consensus EPS -$0.85Beat/MissBeat by +$0.15One Year Ago EPSN/ACrescent Biopharma Revenue ResultsActual Revenue$1.04 millionExpected Revenue$0.36 millionBeat/MissBeat by +$682.00 thousandYoY Revenue GrowthN/ACrescent Biopharma Announcement DetailsQuarterQ1 2026Date4/29/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AUpcoming EarningsCrescent Biopharma's next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Crescent Biopharma Earnings HeadlinesBarbara Harlin Bispham Sells 620 Shares of Crescent Biopharma (NASDAQ:CBIO) StockSeptember 20 at 7:26 AM | americanbankingnews.comEllie Eunkyung Im Sells 623 Shares of Crescent Biopharma (NASDAQ:CBIO) StockSeptember 20 at 7:26 AM | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery.September 20 at 1:00 AM | Behind the Markets (Ad)Jan Pinkas Sells 658 Shares of Crescent Biopharma (NASDAQ:CBIO) StockSeptember 20 at 6:40 AM | americanbankingnews.comJoshua Brumm Sells 1,610 Shares of Crescent Biopharma (NASDAQ:CBIO) StockSeptember 20 at 6:40 AM | americanbankingnews.comJonathan Mcneill Sells 731 Shares of Crescent Biopharma (NASDAQ:CBIO) StockSeptember 20 at 6:40 AM | americanbankingnews.comSee More Crescent Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Crescent Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Crescent Biopharma and other key companies, straight to your email. Email Address About Crescent BiopharmaCrescent Biopharma (NASDAQ:CBIO) (NASDAQ: CBIO) is a biopharmaceutical company focused on discovering and developing innovative therapies for the treatment of serious diseases. The company’s activities center on research, preclinical development and clinical evaluation of investigational drug candidates. Crescent Biopharma does not appear to have commercially marketed products. Its pipeline consists of experimental therapies intended to address significant unmet medical needs, although detailed information about specific candidates, therapeutic areas and development stages may be limited in publicly available sources. The company is headquartered in the United States and serves the biopharmaceutical market through its drug-development programs and potential future partnerships. Additional reliable public information about its history, geographic operations and executive leadership is limited.View Crescent Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
